LENZ Therapeutics, Inc. (LENZ)

Corporate Overview

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. To learn more, please visit www.VIZZ.com.

Our Leadership

Latest Financial Results

Q3 2025

Quarter Ended Sep 30, 2025

Earnings Release PDF

Earnings Webcast

10-Q PDF

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Latest News

Nov 5, 2025 • 8:00 AM EST

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

View Press Release View All News

Recent Event

Nov 5, 2025 8:30 am EST

Lenz Therapeutics Third Quarter 2025 Financial Results and Business Update

View Event View All Events

Email Alerts

Get the latest news and reports delivered right to your inbox.

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449